In this edition, European commission approves Beovu for DME, choroidal vascularity index linked with geographic atrophy progression, intravitreal gene therapy effective, safe in Leber hereditary optic neuropathy, and more. Read the full coverage here: Susvimo noninferior to monthly ranibizumab with similar efficacy European Commission approves Beovu for DME Intravitreal gene therapy effective, safe in Leber hereditary optic neuropathy Teprotumumab may provide better outcomes than IV methylprednisolone in thyroid eye disease Choroidal vascularity index linked with geographic atrophy progression References: Healio Interviews Holekamp NM, et al. Ophthalmology. 2022;doi:10.1016/j.ophtha.2021.09.016. Newman N, et al. The Phase III REFLECT Trial: Efficacy and safety of bilateral gene therapy for Leber hereditary optic neuropathy (LHON). Presented at: American Academy of Neurology Annual Meeting; April 2-7, 2022; Seattle. Press Release Sacconi R, et al. Retina. 2022;doi:10.1097/IAE.0000000000003305.

Ver todos los episodios